Fig. 3From: Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial a Response rate based on subjects reporting a PGI-I score ≤ 2 and b change in HDRS-17 score in patients having received 1 to 3 previous treatments for the current depressive episode. *p < 0.05; **p < 0.01Back to article page